Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The New Political Economy of PharmaceuticalsThe Pharmaceutical Industry, Intellectual Property Rights and Access to Medicines in Pakistan

The New Political Economy of Pharmaceuticals: The Pharmaceutical Industry, Intellectual Property... [The pharmaceutical industry in Pakistan is worth around US$1.18 billion, with annual growth in 2010 approaching 10 per cent (Khan, 2012). There are more than 650 registered companies, including 31 multinationals, which in 2006 had a market share in value terms of 53.3 per cent, with national firms controlling the remaining 46.7 per cent (IMS Health, 2007). In 2007 medicines worth about US$100 million were exported. Medicines are a vital component of healthcare, and Pakistan spends around three-quarters of its healthcare budget on medicines (WHO, 2004). This chapter provides an overview, from a public health perspective, of the national pharmaceutical market and the development of drug policies and regulation. Pakistan adopted a Trade Related Aspects of Intellectual Property Rights (TRIPS)- compliant patent regime in 2000, and the intersection between patents and public health is a central policy challenge. This chapter highlights key issues related to intellectual property, Free Trade Agreements (FTAs), and production and access to medicines.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

The New Political Economy of PharmaceuticalsThe Pharmaceutical Industry, Intellectual Property Rights and Access to Medicines in Pakistan

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/the-new-political-economy-of-pharmaceuticals-the-pharmaceutical-BP52JYShmu
Publisher
Palgrave Macmillan UK
Copyright
© Palgrave Macmillan, a division of Macmillan Publishers Limited 2013
ISBN
978-1-349-32976-2
Pages
167 –184
DOI
10.1057/9781137315854_9
Publisher site
See Chapter on Publisher Site

Abstract

[The pharmaceutical industry in Pakistan is worth around US$1.18 billion, with annual growth in 2010 approaching 10 per cent (Khan, 2012). There are more than 650 registered companies, including 31 multinationals, which in 2006 had a market share in value terms of 53.3 per cent, with national firms controlling the remaining 46.7 per cent (IMS Health, 2007). In 2007 medicines worth about US$100 million were exported. Medicines are a vital component of healthcare, and Pakistan spends around three-quarters of its healthcare budget on medicines (WHO, 2004). This chapter provides an overview, from a public health perspective, of the national pharmaceutical market and the development of drug policies and regulation. Pakistan adopted a Trade Related Aspects of Intellectual Property Rights (TRIPS)- compliant patent regime in 2000, and the intersection between patents and public health is a central policy challenge. This chapter highlights key issues related to intellectual property, Free Trade Agreements (FTAs), and production and access to medicines.]

Published: Nov 6, 2015

Keywords: Intellectual Property; National Health Policy; World Trade Organization; Free Trade Agreement; Pharmaceutical Policy

There are no references for this article.